Abstract

The Protein Chemistry Core will provide the powerful tools of modem mass spectrometry to LPPG? investigators to permit structural identification and quantitation of HDL, SAA, PLTP and HDL-related? biomolecules. In addition to providing instrumental capabilities, Protein Chemistry Core staff will provide? consultation and collaboration on application of mass spectrometry to lipoprotein research, and this will? include development of new analytical methods targeted at achieving research objectives of LPPG? investigators. The Protein Chemistry Core will optimize the efficiency and cost-effectiveness through which? these services are provided LPPG investigators through a central laboratory. This avoids the need for LPPG? investigators to maintain the required instrumentation in their own laboratories and avoids the high cost of? commercial mass spectrometric services. By centralizing and standardizing procedures, the Protein Chemistry? Core will provide a common set of analytical tools that will lead to a unified understanding of molecular? mechanisms involved in lipoprotein metabolism and inflammation-related physiologic and pathophysiologic? processes in the artery wall.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL030086-22
Application #
7551424
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
22
Fiscal Year
2006
Total Cost
$135,459
Indirect Cost

  Institution

Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195

  Publications

Zhang, Meng; Zhai, Xiaobo; Li, Jinping et al. (2018) Structural basis of the lipid transfer mechanism of phospholipid transfer protein (PLTP). Biochim Biophys Acta Mol Cell Biol Lipids 1863:1082-1094
Zhao, Xue-Qiao; Phan, Binh An P; Davis, Joseph et al. (2016) Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. J Clin Lipidol 10:1091-7
Monette, Jeffrey S; Hutchins, Patrick M; Ronsein, Graziella E et al. (2016) Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration. Circ Res 119:83-90
Deguchi, Hiroshi; Wolfbauer, Gertrud; Cheung, Marian C et al. (2015) Inhibition of thrombin generation in human plasma by phospholipid transfer protein. Thromb J 13:24
Rosenthal, Elisabeth; Blue, Elizabeth; Jarvik, Gail P (2015) Next-generation gene discovery for variants of large impact on lipid traits. Curr Opin Lipidol 26:114-9
Shao, Baohai; Tang, Chongren; Sinha, Abhishek et al. (2014) Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res 114:1733-42
Wight, Thomas N; Kinsella, Michael G; Evanko, Stephen P et al. (2014) Versican and the regulation of cell phenotype in disease. Biochim Biophys Acta 1840:2441-51
Zambon, Alberto; Zhao, Xue-Qiao; Brown, B Greg et al. (2014) Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Am J Cardiol 113:1494-8
Phan, Binh An P; Moore, Andrew B; Davis, Joseph et al. (2014) Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). J Clin Lipidol 8:489-93
Vuletic, Simona; Kennedy, Hal; Albers, John J et al. (2014) Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables. Mult Scler Relat Disord 3:533-541

Showing the most recent 10 out of 485 publications